Experience the Most Powerful Generative AI Platform for HEOR & Market Access
ValueGen.AI automates the most time-consuming HEOR and market access tasks — evidence synthesis, economic modeling, HTA intelligence, and payer strategy — with full traceability and domain-specific reliability scoring.
ValueGen.AI — Purpose-Built for HEOR & Market Access
A generative AI platform that automates evidence synthesis, economic modeling, payer strategy, and HTA intelligence — with full traceability and domain-specific reliability scoring.
Health Economics & Outcomes Research
- Economic modeling (CEA, BIM, scenario analysis)
- Automated landscape assessment reports
- Evidence gap identification & prioritization
- Real-world evidence analysis
- ICER / HTA body-specific analyses
- Literature intelligence & evidence synthesis
- Query reliability scoring & validation flags
Strategic Intelligence & Payer Engagement
- HTA insights across 10+ markets (NICE, G-BA, ICER, HAS, CADTH, AIFA, AEM)
- Payer objection handler development
- Value story & payer narrative generation
- Reimbursement landscape intelligence
- Country-specific dossier support
- Competitive intelligence & positioning
- Budget impact & affordability modeling
What ValueGen.AI Produces
Submission-ready outputs across HEOR and market access — in formats your stakeholders already use. Generated in days, not months.
Cost-Effectiveness Model
Markov or decision-tree CEA with PSA, tornado diagrams, ICER outputs, and country-specific threshold analysis.
Budget Impact Model
Payer-level BIM with market uptake, patient share, cost offsets, and scenario toggles.
Online Interactive Model
Browser-based model with sliders and real-time scenario exploration — shareable with payers and HTA bodies.
Landscape Assessment Report
Comprehensive disease-area landscape generated in 48 hours: HTA history, guidelines, and published evidence across 7 markets.
Evidence Gap Analysis
Structured report ranking evidence gaps by strategic priority with recommendations for clinical study design.
Regulatory Submission Summary
Concise clinical evidence narrative for FDA, EMA, or HTA dossier submissions with source citations.
HTA Intelligence Dashboard
Live dashboard tracking HTA decisions, payer positions, and reimbursement status across NICE, G-BA, HAS, ICER, CADTH, AIFA, AEM.
Global Value Dossier
Structured dossier narrative — clinical summary, PICOTS, economic model narrative, and appendices aligned to each HTA body template.
Payer Objection Handler
Q&A document with anticipated payer objections and structured counterarguments on efficacy, durability, and pricing.
Reimbursement Landscape Report
Multi-country reimbursement summary covering coverage, formulary placement, access restrictions, and price benchmarking.
Payer Briefing Note
1–2 page briefing synthesizing clinical evidence, budget impact, and access context for field teams ahead of payer meetings.
Country Adaptation Package
Localized model and narrative adapted to country-specific epidemiology, unit costs, comparators, and HTA methodology.
What Sets ValueGen.AI Apart
Domain depth, traceability, and enterprise-grade reliability — engineered for the regulated workflows of HEOR and market access teams.
Domain-Built, Not Generic
Trained and optimized for HEOR and market access — not a general LLM wrapper. Natively understands HEOR methodologies, NICE appraisal logic, and CEA model structures.
Full Traceability
Every output includes source citations and evidence grounding. Outputs are auditable — essential for regulatory submissions and payer negotiations.
Reliability Scoring
A proprietary framework flags outputs by evidence quality, novelty risk, and domain complexity — telling users exactly when to trust versus verify output.
Wide-Market Coverage
Natively processes HTA reports in French, German, Italian, Spanish, and English — summarizing in English. Covers NICE, G-BA, HAS, ICER, CADTH, AIFA, AEM, and more.
Speed Advantage
Landscape assessments in 48 hours versus months. Objection handlers in minutes. Frees senior experts for high-value strategic work that requires human judgment.
Enterprise-Grade Security
SSO/Auth0, role-based access control, TLS 1.2 encryption, data encrypted at rest. Client data is never used for model retraining or secondary purposes.
AI-powered workflows for evidence generation and economic modeling
From cost-effectiveness analysis and budget impact modeling to evidence synthesis and HTA body-specific analyses — ValueGen.AI accelerates every stage of the evidence lifecycle.
Built around proven HEOR methodologies
- Markov cohort & microsimulation
- Monte Carlo probabilistic sensitivity
- Multi-country model adaptations
- Patient-level simulation models
- Lifetime horizon projections
- HEOR-specific reliability scoring
- Early economic modeling & scoping
Additional capabilities for payer engagement
- Patient access scheme modeling
- Outcomes-based contract framing
- Country-specific dossier narratives
- AMNOG added-benefit argumentation
- Patient advocacy alignment analysis
- Coverage with evidence development
- Multi-stakeholder objection simulation
Strategic intelligence and payer engagement at speed
AI-driven insights for reimbursement strategy, HTA navigation, payer communication, and competitive positioning — across NICE, G-BA, HAS, ICER, CADTH, AIFA, and AEM and more.
Trusted by Leading Life Sciences Organizations
Partnering with global leaders across pharma, biotech, and health technology assessment.
Ready to Transform Your HEOR & Market Access Workflows?
ValueGen.AI replaces months of manual effort with AI-powered workflows that HEOR and market access professionals can trust and act on immediately.
Get Started